Literature DB >> 21812935

Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats.

Annamaria Morelli1, Erica Sarchielli, Paolo Comeglio, Sandra Filippi, Rosa Mancina, Mauro Gacci, Linda Vignozzi, Marco Carini, Gabriella B Vannelli, Mario Maggi.   

Abstract

INTRODUCTION: In humans, prostate phosphodiesterase type 5 inhibitors (PDE5) expression was prominently localized in the endothelial and smooth muscle cells of the vascular bed, suggesting a possible action of PDE5 inhibitors (PDE5i) on prostate blood flow. AIM: To investigate PDE5 expression in human and rat lower urinary tract (LUT) tissues, including vasculature, and determine the effects of PDE5 inhibition with tadalafil on prostatic blood perfusion. MAIN OUTCOME MEASURES: Human vesicular-deferential arteries (which originate from the inferior vesical artery, the main arterial source of blood supply to the bladder and prostate) were analyzed for PDE5 expression and activity. The effects of tadalafil on prostate oxygenation were studied in spontaneously hypertensive rats (SHR), characterized by ischemia/hypoxia of the genitourinary tract.
METHODS: PDE5 expression was evaluated by quantitative reverse transcription-polymerase chain reaction and immunohistochemistry. SHR were treated with tadalafil (2 mg/kg/day) for 1, 7, or 28 days and compared with untreated SHR and the unaffected counterpart Wistar-Kyoto (WKY) rats. Prostate oxygenation was detected by Hypoxyprobe-1 and hypoxia markers (hypoxia-inducible factor-1α[HIF-1α] and endothelin-1 type B [ETB]) immunostaining.
RESULTS: Human vesicular-deferential artery expressed high levels of PDE5, similar to corpora cavernosa, immunolocalized in the endothelial and smooth muscle layer. In these arteries, tadalafil inhibited cyclic guanosine monophosphate breakdown (half maximal inhibitory concentration (IC(50) ) in the low nanomolar range, as in corpora cavernosa) and increased the relaxant response to sodium nitroprusside. SHR prostate resulted markedly hypoxic (hypoxyprobe immunopositivity) and positive for HIF-1α and ETB, while tadalafil treatment restored oxygenation to WKY level at each time point. The mRNA expression of the HIF-1α target gene, BCL2/adenovirus E1B 19 kDa interacting protein 3, was significantly increased in SHR prostate and partially restored to WKY level by tadalafil.
CONCLUSION: Human vesicular-deferential artery is characterized by a high expression and activity of PDE5, which was inhibited by tadalafil in vitro. In SHR, tadalafil increases prostate tissue oxygenation, thus suggesting a possible mechanism through which PDE5i exert beneficial effects on LUT symptoms.
© 2011 International Society for Sexual Medicine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21812935     DOI: 10.1111/j.1743-6109.2011.02416.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  44 in total

1.  Therapy: two birds, one stone: tadalafil is an effective treatment for men with both BPH-LUTS and ED.

Authors:  Nick Warde
Journal:  Nat Rev Urol       Date:  2011-11-15       Impact factor: 14.432

Review 2.  The use of PDE-5 inhibitors in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.

Authors:  Casey Lythgoe; Kevin T McVary
Journal:  Curr Urol Rep       Date:  2013-12       Impact factor: 3.092

Review 3.  [Bladder storage and voiding dysfunctions : Side effects of drug therapy].

Authors:  J Wolfesberger; C E Falkensammer; S Madersbacher
Journal:  Urologe A       Date:  2017-04       Impact factor: 0.639

4.  Do AB0 blood groups affect lower urinary tract symptoms?

Authors:  Erdal Benli; Abdullah Çırakoğlu; Ercan Öğreden; Yasemin Kaya; Ali Ayyıldız; Ahmet Yüce
Journal:  Turk J Urol       Date:  2018-11-19

Review 5.  Management of benign prostatic hyperplasia: role of phosphodiesterase-5 inhibitors.

Authors:  M Gacci; M Carini; M Salvi; A Sebastianelli; L Vignozzi; G Corona; M Maggi; K T McVary; S A Kaplan; M Oelke; S Serni
Journal:  Drugs Aging       Date:  2014-06       Impact factor: 3.923

6.  Singapore Urological Association Clinical Guidelines for Male Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia.

Authors: 
Journal:  Singapore Med J       Date:  2017-08       Impact factor: 1.858

Review 7.  Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS.

Authors:  Selim Cellek; Norman E Cameron; Mary A Cotter; Christopher H Fry; Dapo Ilo
Journal:  Nat Rev Urol       Date:  2014-03-11       Impact factor: 14.432

Review 8.  The role of phosphodiesterase type-5 inhibitors in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.

Authors:  Mehmet Umul; Tekin Ahmet Serel
Journal:  Turk J Urol       Date:  2013-12

Review 9.  Phosphodiesterase-5 expression and function in the lower urinary tract: a critical review.

Authors:  Ching-Shwun Lin; Maarten Albersen; Zhongcheng Xin; Mikio Namiki; Dieter Muller; Tom F Lue
Journal:  Urology       Date:  2013-01-17       Impact factor: 2.649

Review 10.  A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction.

Authors:  Konstantinos Hatzimouratidis
Journal:  Ther Adv Urol       Date:  2014-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.